renal-cell carcinoma (advanced)

Description Results NMA

PFS 0.71 [0.61; 0.83]

OS 0.86 [0.73; 1.01]

PFS 0.63 [0.52; 0.76]

OS 0.86 [0.72; 1.03]

bevacizumab (10 mg/kg intravenously every 2 weeks) plus IFN- (9 million units subcutaneously three times weekly) (n=369)

vs.

same dose and schedule of IFN- monotherapy (n=363)

Parallel groups

Sample size: 369/363

Primary endpoint: OS

FU duration:

bevacizumab (10 mg/kg every 2 weeks) plus IFN (9 MIU subcutaneously three times a week) (n=327)

vs.

IFN plus placebo (n=322)

Sample size: 327/322

Primary endpoint:

FU duration:

bevacizumab at doses of 3 and 10 mg per kilogram of body weight, given every two weeks (n=76)

vs.

placebo (n=40)

Parallel groups

Sample size: 76/40

Primary endpoint:

FU duration:

OS 0.73 [0.57; 0.93] median 25.0 mo vs. 19.6 mo

PFS 0.88 [0.75; 1.03] median 4.6 mo vs. 4.4 mo

OS 0.68 [0.49; 0.95] median not reached vs. 32.9 mo Demonstrated

PFS 0.82 [0.64; 1.05] median 11.56 mo vs. 8.38 mo

3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks (n=-9)

vs.

10-mg everolimus tablet orally once daily (n=-9)

open-label

Parallel groups

Sample size: -9/-9

Primary endpoint: OS

FU duration:

nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by Opdivo 3 mg/kg every 2 weeks (n=-9)

vs.

sunitinib 50 mg once daily for 4 weeks, followed by 2 weeks off before continuation of treatment (n=-9)

open-label

Parallel groups

Sample size: -9/-9

Primary endpoint: ORR, PFS, OS

FU duration:

phase 3

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

PFS 0.67 [0.54; 0.81]

axitinib (n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

OS 0.67 [0.51; 0.89]

PFS 0.58 [0.45; 0.75]

PFS 0.66 [0.46; 0.95] median 8.2 mo vs. 5.6 mo

cabozantinib at a dose of 60 mg daily (n=330)

vs.

everolimus at a dose of 10 mg daily (n=328)

open-label

Parallel groups

Sample size: 330/328

Primary endpoint: PFS

FU duration:

phase 3

cabozantinib (60 mg once per day) (n=79)

vs.

sunitinib (50 mg once per day; 4 weeks on, 2 weeks off). (n=78)

open-label

Parallel groups

Sample size: 79/78

Primary endpoint: PFS

FU duration:

phase 2

PFS 0.86 [0.72; 1.03]

dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule) (n=284)

vs.

sorafenib (400 mg orally twice daily) (n=286)

open-label

Sample size: 284/286

Primary endpoint:

FU duration:

PFS 0.46 [0.34; 0.62]

PFS 0.46 [0.34; 0.62]

OS 0.91 [0.71; 1.16]

OS 0.91 [0.76; 1.08]

PFS 1.05 [0.90; 1.22]

pazopanib (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint: PFS

FU duration:

(n=290)

vs.

(n=145)

Sample size: 290/145

Primary endpoint: PFS

FU duration:

continuous dose of pazopanib (800 mg once daily) (n=557)

vs.

sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment) (n=553)

Parallel groups

Sample size: 557/553

Primary endpoint: PFS

FU duration:

PFS 0.88 [0.61; 1.27]

PFS 0.44 [0.35; 0.55]

OS 0.88 [0.74; 1.04]

oral sorafenib 400 mg twice daily (n=97)

vs.

subcutaneous IFN--2a 9 million U three times weekly (n=92)

Parallel groups

Sample size: 97/92

Primary endpoint:

FU duration:

phase 2

continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) (n=451)

vs.

placebo (n=452)

Parallel groups

Sample size: 451/452

Primary endpoint: OS

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

PFS 0.42 [0.32; 0.55]

OS 0.82 [0.67; 1.00]

repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) (n=375)

vs.

interferon alfa (at a dose of 9 MU given subcutaneously three times weekly). (n=375)

Sample size: 375/375

Primary endpoint: PFS

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

PFS 0.80 [0.64; 0.99]

OS 1.25 [0.95; 1.63]

tivozanib (n=260)

vs.

sorafenib (n=257)

Sample size: 260/257

Primary endpoint: PFS

FU duration: